Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial.


Journal

Scandinavian journal of clinical and laboratory investigation
ISSN: 1502-7686
Titre abrégé: Scand J Clin Lab Invest
Pays: England
ID NLM: 0404375

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 7 5 2020
medline: 20 7 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

Carbohydrate-restricted diets are increasingly recognized as options for dietary management of type 2 diabetes mellitus (T2DM). We investigated the effects of a carbohydrate-reduced high-protein (CRHP) and a conventional diabetes (CD) diet on oxidative stress and inflammation in weight stable individuals with T2DM. We hypothesized that the CRHP diet would improve markers of oxidatively generated RNA and DNA modifications as well as inflammatory parameters. Thirty participants with T2DM were randomized to 6 weeks of CRHP or CD dietary treatment (30/50 energy percentage (E%) carbohydrate, 30/17E% protein, 40/33E% fat), followed by a cross-over to the opposite diet for a subsequent 6-week period. All meals were provided during the study and body weight was controlled. Diurnal urine samples were collected after 4 weeks on each diet and oxidatively generated RNA and DNA modifications were measured as 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), respectively. Fasting concentrations of soluble urokinase plasminogen activator receptor, high-sensitivity C-reactive protein, tumor necrosis factor alpha and interleukin-6 were measured before and after 6 weeks of interventions. Compared with the CD diet, the CRHP diet increased 24-hour urinary excretion of 8-oxoGuo by 9.3% (38.6 ± 12.6 vs. 35.3 ± 11.0 nmol/24 h,

Identifiants

pubmed: 32374188
doi: 10.1080/00365513.2020.1759137
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0
IL6 protein, human 0
Interleukin-6 0
Nucleic Acids 0
Receptors, Urokinase Plasminogen Activator 0
Tumor Necrosis Factor-alpha 0
hemoglobin A1c protein, human 0
Guanosine 12133JR80S
8-hydroxyguanosine 3868-31-3
8-Hydroxy-2'-Deoxyguanosine 88847-89-6
C-Reactive Protein 9007-41-4

Types de publication

Clinical Trial Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

401-407

Auteurs

Mads Juul Skytte (MJ)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Amirsalar Samkani (A)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Arne Astrup (A)

Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.

Thomas Meinert Larsen (TM)

Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.

Jan Frystyk (J)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Henrik Enghusen Poulsen (HE)

Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Trine Henriksen (T)

Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Jens Juul Holst (JJ)

Novo Nordisk Foundation Center for Basic Metabolic Research, and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Ove Andersen (O)

Clinical Research Centre and the Emergency Department, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

Sten Madsbad (S)

Department of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

Steen Bendix Haugaard (SB)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Thure Krarup (T)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Emil List Larsen (EL)

Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH